Pepwizard
Market intelligence

Who actually makes your peptides

The peptide boom has a supply chain most buyers never see. Indian API manufacturers, Swiss pharmaceutical CDMOs, Chinese raw-material producers, and Japanese discovery platforms. Here's the invisible chemistry stack behind the vial you just ordered.

The three-layer model

  1. Raw material + precursors — Chinese and Indian specialty-chemical firms supply Fmoc-protected amino acids and fatty-acid side chains. This is the ApiSyn / Ami Organics layer.
  2. API synthesis — peptide APIs are produced at scale by Indian CDMOs (Neuland, Morepen) and Swiss / Chinese pharmaceutical manufacturers.
  3. Finishing + quality — Swiss and EU CDMOs (Bachem primarily) finish licensed pharmaceutical peptides. Research-peptide vendors typically short-circuit this layer with direct-to-consumer fulfilment.

Companies building depth

Ami Organics

India · publicly listed
site ↗

Advanced pharmaceutical intermediates, fatty-acid side-chain chemistry

Peptide focus: GLP-1 side chains, intermediates for semaglutide and tirzepatide

ApiSyn Healthcare

India (Ahmedabad) · private

Commercial-scale Fmoc-protected amino acids — foundational inputs for SPPS

Peptide focus: Solid-phase peptide synthesis precursors across the entire catalogue

Neuland Labs

India · publicly listed
site ↗

USFDA + EDQM-accredited pure-play peptide API maker

Peptide focus: Semaglutide and tirzepatide in pipeline; active peptide API portfolio

Morepen Labs

India · publicly listed
site ↗

Scaling peptide API with USFDA-approved facilities

Peptide focus: Diabetes and metabolic peptide APIs for regulated markets

Bachem

Switzerland · publicly listed
site ↗

Global pharmaceutical peptide CDMO; finishing / QC for regulated markets

Peptide focus: Licensed pharmaceutical peptides — semaglutide, liraglutide finishing

PeptiDream

Japan · publicly listed
site ↗

Discovery platform for novel peptide drugs

Peptide focus: Next-generation therapeutic peptides via mRNA display

GenScript Biotech

China / US · publicly listed
site ↗

Custom peptide synthesis + life-sciences B2B supply

Peptide focus: Research-grade and custom peptides at scale

What this means for you

Four downstream implications:

  1. API scarcity isn't imminent. Indian capacity is scaling faster than consumer demand.
  2. Expect new GLP-1 generics. Once the semaglutide patent cliff lands, the Indian API makers are ready.
  3. Vertical integration is coming. Brand-level vendors will partner with or acquire API producers directly.
  4. Quality variance will tighten. More manufacturing visibility, more per-batch COAs, more pressure on the research-chemical vendors to catch up.

For investors

Publicly listed pure-plays to watch: Neuland Labs (NSE), Ami Organics (NSE), Morepen Labs (BSE/NSE), PeptiDream (TSE 4587), Bachem (SIX BANB), GenScript (HKEX 1548). These are the picks-and-shovels of the peptide economy.

Want to buy the actual output?

Our price matrix tracks every vendor selling material from the chain above.

Open the price matrix →